Diagnostic Criteria for Obstetric Antiphospholipid Syndrome
Obstetric APS requires at least one clinical obstetric criterion AND persistent antiphospholipid antibodies (confirmed positive on two occasions at least 12 weeks apart), with the 2023 ACR/EULAR criteria now emphasizing preeclampsia and placental insufficiency as the key pathophysiologic mechanisms rather than isolated fetal losses. 1
Clinical Criteria (Obstetric Manifestations)
The obstetric criteria have evolved significantly with the 2023 classification update. The key shift is recognizing that obstetric APS manifestations primarily result from preeclampsia and placental insufficiency, not simple thrombosis 1:
Accepted Clinical Criteria:
- Fetal death ≥10 weeks gestation with evidence of preeclampsia and/or placental insufficiency 1
- Premature birth <34 weeks due to severe preeclampsia, eclampsia, or placental insufficiency 1
- Three or more consecutive spontaneous abortions <10 weeks gestation (after excluding anatomic, hormonal, and chromosomal causes) 2
- Intrauterine growth restriction secondary to placental insufficiency 1
Critical Change from Previous Criteria:
Isolated fetal death without preeclampsia and/or placental insufficiency now has little diagnostic significance 1. This represents a major departure from older criteria and reflects improved understanding that obstetric APS is fundamentally a disorder of placental vascular dysfunction, not just thrombosis.
Laboratory Criteria
Persistent antiphospholipid antibodies must be documented on two separate occasions at least 12 weeks apart 3, 2:
Required Antibody Testing:
- Lupus anticoagulant (LA) - the strongest risk factor for both thrombotic and obstetric complications 3, 1
- Anticardiolipin antibodies (aCL) - IgG or IgA isotypes
- Anti-β2-glycoprotein I antibodies (aβ2GPI) - IgG or IgA isotypes
Important Threshold Changes (2023 ACR/EULAR):
- Moderate titer threshold: ≥40 Units 3
- High titer threshold: ≥80 Units 3
- The 99th percentile cutoff calculation has been abandoned 3
- Isolated IgM isotype aCL or aβ2GPI antibodies are no longer sufficient for classification due to weak association with clinical manifestations 1
- IgG antibodies <40 GPL are insufficient for APS classification 1
Risk Stratification for Obstetric APS
High-risk antibody profiles that predict worse outcomes 2:
- Lupus anticoagulant positivity (strongest predictor) 3, 1
- Triple positivity (LA + aCL + aβ2GPI)
- Moderate to high titer antibodies (≥40 Units)
- Multiple positive antibodies
Additional maternal risk factors 2:
- Coexisting systemic lupus erythematosus
- History of previous thrombotic APS
- History of previous adverse pregnancy complications
- Hypertension
Critical Diagnostic Pitfalls
Classification vs. Clinical Diagnosis:
These classification criteria are designed for research homogeneity, NOT for excluding patients from treatment in clinical practice 3, 1. The 2023 criteria prioritize specificity over sensitivity, meaning some patients with genuine obstetric APS may not meet classification criteria but still require treatment 1.
Laboratory Considerations:
- False positives can occur with infections, medications, and other conditions 4
- Testing asymptomatic individuals is not recommended except in systemic lupus erythematosus 4
- Lack of standardization between laboratory methods remains a significant challenge 3, 4
- Transient antibody positivity does not constitute APS - persistence is mandatory 5
When to Test:
- Recurrent pregnancy loss (≥3 consecutive losses <10 weeks)
- Unexplained fetal death ≥10 weeks
- Severe or early preeclampsia
- Severe placental insufficiency
- Premature birth <34 weeks due to placental complications
- Unexplained intrauterine growth restriction
Distinction Between Classification and Clinical Care
In real-world practice, clinicians should not rigidly apply classification criteria to deny treatment 3, 1. Patients falling outside the 2023 criteria may still benefit from treatment based on:
- Individual antibody profile strength
- Clinical context and risk factors
- Shared decision-making with careful explanation of risks and benefits 1
The emphasis on preeclampsia and placental insufficiency in the new criteria reflects the true pathophysiology of obstetric APS, where trophoblast dysfunction, inflammation, and decidual microenvironmental dysfunction are now recognized as critical mechanisms beyond simple thrombosis 6.